Cover Image
Market Research Report

Global Hepatitis C Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 778256
Published Content info 113 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Hepatitis C Drugs Market 2019-2023
Published: January 4, 2019 Content info: 113 Pages
Description

About this market:

The increasing number of voluntary licensing agreements to drive market growth. Voluntary licensing helps in improving access to essential medicines. Under the voluntary licensing agreement, patent holders license others to manufacture, import, and/or distribute their patented drugs. Voluntary licenses enable the development of generic versions of drugs, which increases the affordability and access to the patients. Technavio's analysts have predicted that the hepatitis C drugs market to register a revenue of around USD 5.7 billion by 2023.

Market Overview:

Increasing demand for direct-acting antiviral

Direct-acting antiviral drugs have emerged as a curative option for patients with hepatitis C. These drugs act and block specific steps in the lifecycle of the HCV. They are known to target the specific nonstructural proteins of the virus that results in the disruption of viral replication. Thus, they show comparatively fewer side effects than the interferons, which were employed until the advent of direct-acting antiviral drugs.

Side effects of available drugs

The interferons indicated for the treatment of hepatitis C are known to be associated with harmful side effects such as excessive fatigue, headache, weight loss, alopecia, autoimmune disorders, high blood pressure, slowed growth in children, changes in vision, and malfunctioning of the lungs, liver, and pancreas. Due to these side effects, the interferon therapy is replaced by direct-acting antivirals at present.

For the detailed list of factors that will drive and challenge the growth of the hepatitis C drugs market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be fragmented and with the presence of several companies including Gilead and Merck the competitive environment is quite intense. Factors such as the increasing demand for direct-acting antiviral and the increasing number of voluntary licensing agreements, will provide considerable growth opportunities to hepatitis C drugs manufactures. AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead, and Merck are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR30642

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1. Preface
  • 2.2. Preface
  • 2.3. Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

  • Acute hepatitis C
  • Chronic hepatitis C

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • Merck

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global infectious disease treatment market
  • Exhibit 03: Segments of global infectious disease treatment market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Molecules in Phase III and Phase II stages of evaluation for hepatitis C treatment
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2018
  • Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Product - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by product
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Key leading countries
  • Exhibit 36: Market opportunity
  • Exhibit 37: Decision framework
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Vendor landscape
  • Exhibit 40: Landscape disruption
  • Exhibit 41: Vendors covered
  • Exhibit 42: Vendor classification
  • Exhibit 43: Market positioning of vendors
  • Exhibit 44: AbbVie - Vendor overview
  • Exhibit 45: AbbVie - Business segments
  • Exhibit 46: AbbVie - Organizational developments
  • Exhibit 47: AbbVie - Geographic focus
  • Exhibit 48: AbbVie - Key offerings
  • Exhibit 49: Bristol-Myers Squibb - Vendor overview
  • Exhibit 50: Bristol-Myers Squibb - Business segments
  • Exhibit 51: Bristol-Myers Squibb - Organizational developments
  • Exhibit 52: Bristol-Myers Squibb - Geographic focus
  • Exhibit 53: Bristol-Myers Squibb - Key offerings
  • Exhibit 54: F. Hoffmann-La Roche - Vendor overview
  • Exhibit 55: F. Hoffmann-La Roche - Business segments
  • Exhibit 56: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 57: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 58: F. Hoffmann-La Roche - Segment focus
  • Exhibit 59: F. Hoffmann-La Roche - Key offerings
  • Exhibit 60: Gilead - Vendor overview
  • Exhibit 61: Gilead - Business segments
  • Exhibit 62: Gilead - Organizational developments
  • Exhibit 63: Gilead - Geographic focus
  • Exhibit 64: Gilead - Key offerings
  • Exhibit 65: Merck - Vendor overview
  • Exhibit 66: Merck - Business segments
  • Exhibit 67: Merck - Organizational developments
  • Exhibit 68: Merck - Geographic focus
  • Exhibit 69: Merck - Segment focus
  • Exhibit 70: Merck - Key offerings
  • Exhibit 71: Validation techniques employed for market sizing
  • Exhibit 72: List of abbreviations
Back to Top